ArticleAnnals of Indian Academy of Neurology2026
Neurofascin Antibodies in a Large Cohort of Inflammatory Neuropathies from India.
Article in Annals of Indian Academy of Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesInflammatory neuropathies are a heterogeneous group of disorders of the peripheral nerves. Pathogenic antibodies targeting various antigens at the node-paranode junctions, leading to its disorganization, are increasingly recognized as accounting for an important subset of inflammatory neuropathies. Among these, antibodies against neurofascin (NF)155 and NF186 are the most widely recognized. The current study aimed to determine the prevalence of NF155 and NF186 antibodies in an Indian cohort of patients with inflammatory neuropathies.
methodsSeventy-six patients with inflammatory neuropathies, including 44 with Guillain-Barré syndrome (GBS) and 32 with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and 32 healthy controls were recruited. NF155 and NF186 antibodies were tested in sera from all study participants.
resultsIn this study, 8/76 (10.53%) patients with inflammatory neuropathies tested positive for NF186 antibodies, including 5 (11.36%) with GBS and 3 (9.37%) with CIDP. Given the small sample size, definitive differences between the NF186 antibody-positive and antibody-negative groups could not be established. None of the patients with GBS and NF186 antibody positivity required mechanical ventilation. None of the patients with CIDP and NF186 antibody positivity had an acute GBS-like onset. One patient in the NF186 antibody-positive CIDP group had the phenotype of combined central and peripheral demyelination. None of the study participants tested positive for NF155 antibodies.
conclusionsA higher proportion of GBS patients showed NF186 reactivity in the present study than in previous reports. The spectrum of other pathogenic antibodies remains to be tested, as the majority of patients with inflammatory neuropathies tested negative for the two NF antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.